WINNERGY MEDICAL PUBLIC COMPANY LIMITEDSET: WINMED🇹🇭 TH

Business Operation · 2025

Corporate Information

Company Name

WINNERGY MEDICAL PUBLIC COMPANY LIMITED

Telephone

0-2725-0888

Website

http://www.winmed.com

Email

ir@winnergy.co.th

Dividend Policy

Dividend Policy

The Company has a policy to pay dividends not less than 40% of the remaining net profit from all types of reserves as required by laws and the Company. The dividends are considered from the net profit according to the Company’s separate financial statements for each business, depending on the operational plan, financial position, liquidity, business expansion plan, other necessities and appropriateness in the future. Also, the payment of dividends shall not have any significant effects on normal operations of the Company and its subsidiaries, as deemed appropriate by the Board of Directors and/or shareholders.

The Board of Directors shall consider the payment of dividends mainly based on the benefits to shareholders and must be presented for approval at the shareholders’ meeting, except the payment of interim dividends.

The Board of Directors has its power to consider and occasionally approve the payment of interim dividends when seeing that the Company is profitable and shall report for acknowledgment at the next shareholders’ meeting.

Historical Dividend Payments

This YearLast Year2 Years Ago3 Years Ago4 Years AgoMetricDescription
0.040.070.080.150.18Net profit per share (Baht : Share)Net profit per share (baht : share)
0.010.020.030.060.07Dividend per share (Baht : Share)Dividend per share (baht : share)
00000Dividend stock ratio (Number of original shares: dividend shares)Ratio of stock dividend payment (existing share : stock dividend)
00000Dividend share value per share (Baht : Share)Value of stock dividend per share (baht : share)
00000Total dividend payment value (Baht : Share)Total dividend payment (baht : share)
00000Dividend payout ratio to net profit (%)Dividend payout ratio compared to net profit (%)

Major Shareholders

Major Shareholders

No.NameShares% Shares
20,512Winnergy Trading Company Limited 182,785,82045.7
23,962DARA INVESTMENT LIMITED54,598,32013.65
23,963D.D.S. Jinhatha Panyasorn38,954,8609.74
23,964Mr. Kamchai Nampaisarn8,100,0002.03
23,965Mr. Prapan Vilailert 4,934,6001.23
23,966Mr. Nanthiya Darakananda4,334,7601.08
24,101Mr. Prasert Limviriyalerd 3,528,6000.88
24,102Mrs. Kanmanee Eamveerawong 2,528,4000.63
24,103Mr. Phawawit Klinprathum2,065,0000.52
24,104Ms. Chantarawan Charuntham2,052,0000.51

Remark

Remark: (1) Information from Thailand Securities Depository Co., Ltd. (2) Winnergy Trading Co., Ltd. is a Non-Operating Holding Company with the purpose of investing in other businesses in the future. It is 51% owned by Winnergy Digital Co., Ltd. (which is wholly owned by Mr. Sumeth Darakanon, the father of Khun Nantaya Darakanon) and 49% owned by Dara Investment Limited. (3) Dara Investment Limited is a company established under the laws of the Hong Kong Special Administrative Region of the People's Republic of China. It is 100% owned by Dara International Inc. (which is wholly owned by Mr. Sumeth Darakanon, the father of Khun Nantaya Darakanon).

Business Strategies Overview

Vision

All people in Thailand with substantially happier, healthier and longer life - through the use of our globally curated advanced medical technologies.

Objectives

The business operates under the “Meaningful Purpose” concept, prioritizing the creation of genuine health value for the Thai people through the development and provision of high-quality, safe, and accessible medical technologies. The Company is committed to reducing public health inequality and promoting access to standardized screening, diagnosis, and treatment. By synergizing with partners across all sectors and empowering our employees, we aim to create superior value through true collaboration (Winning Together Through Synergy).

Goals

1. Zero death from cancer through effective detection and treatment.

2. Safe and sufficient blood for every life in Thailand.

Business Strategies

The Company adopts its core values as a guiding framework for formulating strategies and business operations, with the aim of fostering a responsible and transparent working culture and driving the organization toward shared success. The details are as follows:

IMPACT

I - Initiate with Intent

M - Maintain Mindful Awareness

P - Proactively Solve and Prevent Problems

A - Act with Accountability

C - Communicate for Clarity

T - Team Up for Shared Success

The Company adopts its core values as guiding principles in formulating operational strategies, with the aim of fostering a responsible and transparent work culture and driving shared success.

Material Changes & Developments

Material Changes & Developments

YearDescription
2,023
  • January: Launched the “Pedsupap” page to disseminate knowledge on sexual health for people of all genders and all age groups.

  • March: Established the second mobile blood donation unit in collaboration with Roi Et Hospital.

  • May: Received a certificate confirming compliance with the Personal Data Protection Act B.E. 2562 (2019) (PDPA).

  • July: Appointed as an authorized distributor of products from NanoEntek, South Korea.

  • October: Signed a Memorandum of Understanding (MOU) to support cervical cancer screening in collaboration with the Nakhon Ratchasima Provincial Administrative Organization.

  • December: Signed a Memorandum of Understanding (MOU) to support cervical cancer screening in collaboration with the Provincial Administrative Organizations of Kamphaeng Phet and Kanchanaburi.

2,024
  • January: Achieved ISO/IEC 27001:2022 certification and obtained a healthcare facility operating license under the name “Winmed Sah Clinic.”

  • February: Launched Thailand’s first Mobile Colposcopy health screening vehicle for confirmatory cervical cancer diagnosis, with initial services provided in Kamphaeng Phet Province.

  • March: Enhanced its capacity as an HPV specimen collection unit accredited by the National Health Security Office (NHSO), and signed memorandum of understanding (MOU) with the Provincial Administrative Organizations of Prachinburi and Nakhon Si Thammarat.

  • April: Launched the “WINMED Giving with Heart for Life” project in collaboration with Ramathibodi Hospital to operate mobile blood and platelet donation units.

  • April: Signed Memorandum of Understanding (MOU) to support cervical cancer screening in collaboration with the Provincial Administrative Organizations of Phatthalung and Chanthaburi.

  • June: Launched the “Winmed Cares” project, offering free HPV self-sampling kits for cervical cancer screening to Thai women aged 30–59.

  • October: Conducted mobile health screening services, providing testing for hepatitis B and C, HIV, colorectal cancer, and cervical cancer.

  • October: Launched a breast cancer screening program using THERMOGRAM.AI technology, an innovative screening method that is convenient, safe, painless, and ensures privacy.

2,025
  • Certified with important international standards, including:

    1. Good Distribution Practice (GDP) for the storage and distribution of medical products, particularly pharmaceuticals and medical supplies

    2. Occupational Health and Safety Management System (ISO 45001:2018)

    3. Road Traffic Safety Management System (ISO 39001:2012)

  • Launched the first mobile breast cancer screening unit using Thermogram AI technology to expand access to proactive screening services for the public

  • Established the “342 Club” page as a communication channel for product information, activities, and customer engagement

  • Expanded collaboration with Provincial Administrative Organizations (PAOs) across multiple regions to implement cervical cancer and other disease screening programs, with Memorandums of Understanding (MOUs) signed with Prachinburi, Suphan Buri, Nakhon Sawan, Prachuap Khiri Khan, Chaiyaphum, Mukdahan, Rayong, Amnat Charoen, Nakhon Phanom, and Kalasin, bringing the total number of partnered provinces to 22.

  • Collaborated with the National Blood Center, Thai Red Cross Society, to present Intercept PI (Pathogen Inactivation) technology at the 31st National Scientific Conference on Blood Transfusion Services, promoting platelet safety

  • Expanded mobile blood and platelet donation programs using automated collection systems across 9 hospitals, bringing the total number of partnered hospitals to 20 nationwide

  • Partnered with private sector organizations to provide breast cancer screening services using Thermogram AI technology for the first time

  • Celebrated the successful implementation of breast cancer screening programs using Thermogram AI, which utilizes artificial intelligence (AI) for analysis

  • Transitioned certain contracts in line with government guidelines from “unlimited reagent purchase agreements” (revenue recognized upon delivery) to “medical equipment rental agreements,” with monthly payments based on completed test reports, resulting in changes to revenue recognition

  • Entered into an MOU for research and development with the Thai Gynecologic Cancer Society, introducing AI-powered colposcope technology (AI Colposcope) for studying cervical abnormalities. The project is being conducted in collaboration with 16 leading medical institutions nationwide, with support in software systems, AI services, and academic knowledge to enhance screening efficiency and improve access to medical services for the public.

Use of Proceeds from Securities Offerings

Is There Money Raised from a Securities Offering Still to Report On?

Yes

Offerings

Type of SecuritiesAmount Raised Given AsAmount Raised (Million Baht)Uses of the MoneyUsed as Declared?
Equity Instruments2873349.482025-06-30 · Objective: Invest in construction a laboratory to detect HPV through a self-collection kit for collecting abnormal cervical cell from the vagina. · Period type: 2869 · Start period: 2025-01-01 · Spent amount type: 2873 · Start spent amount: 18.0 · Expected amount type: 2873 · Start expected amount range: 18.0 · 2025-06-30 · Objective: Invest in the construction of a laboratory to prepare cell products for cell therapy. · Period type: 2869 · Start period: 2025-01-01 · Spent amount type: 2873 · Start spent amount: 38.08 · Expected amount type: 2873 · Start expected amount range: 38.08 · 2025-06-30 · Objective: Invest in the construction of a laboratory for the detection of coronavirus 2019. · Period type: 2869 · Start period: 2025-01-01 · Spent amount type: 2873 · Start spent amount: 17.76 · Expected amount type: 2873 · Start expected amount range: 17.76 · 2025-06-30 · Objective: Repay the loan · Period type: 2869 · Start period: 2025-01-01 · Spent amount type: 2873 · Start spent amount: 200.0 · Expected amount type: 2873 · Start expected amount range: 200.0 · 2025-06-30 · Objective: Invest in Polyclinic · Period type: 2869 · Start period: 2021-01-01 · Spent amount type: 2873 · Start spent amount: 7.67 · Expected amount type: 2873 · Start expected amount range: 7.67 · 2024-12-31 · Objective: Use as working capital · Period type: 2869 · Start period: 2021-01-01 · Spent amount type: 2873 · Start spent amount: 67.97 · Expected amount type: 2873 · Start expected amount range: 67.97Y

Commitments Made in the Registration Statement

Are There Commitments or Conditions from an Offering or Listing?

No

Group Operating-Structure Policy

Description

The companies within the group have organized their operations according to the defined structure, enabling each unit to conduct business efficiently, in line with the group’s strategy, and minimizing redundancies in management.

Companies Where the Company Holds ≥10%

Companies (≥10% Holding)

Company NameAddressProvinceZip CodeTelephoneFaxBusiness TypeSecurity TypeSharesPaid-up Shares
A New Day Company Limited (AND)No. 634/4 Soi Ramkhamhaeng 39 (Thepleela 1), Pracha Uthit Road Wang Thonglang Sub-district, Wang Thonglang District, BangkokBangkok10310027250888 027250880Distribute scientific and technology products related to health and hygiene.Common shares3,300,0003,300,000

Shareholders with Potential Conflict of Interest

Has Potential-Conflict Shareholder (Y/N)

No

Relationships Among Major Shareholders

Relationship Exists (Y/N)

Yes

Description

The Company’s major shareholders are Winnergy Trading Co., Ltd. and Dara Investment Limited, holding 45.70% and 13.65% of the company’s total issued shares, respectively.

However, the company’s core business operations are not significantly related or connected to the other businesses of its major shareholders. Any relationships occur only occasionally in transactions with related parties, with details provided under the section on related-party transactions.

Shareholders' Agreement

Agreement Exists (Y/N)

No

Shareholding Diagram (Group Structure)

Does the company hold shares in other companies?

Yes

Subsidiaries

Company NameJuristic Persons / Holders
A New Day Company Limited (AND)WINNERGY MEDICAL PUBLIC COMPANY LIMITED · Voting rights percent: 99.99 · Shareholding proportion percent: 99.99

Income Structure

Product / Service Income

CategoryDescriptionThis YearThis Year %Last YearLast Year %2 Years Ago2 Years Ago %
Total revenue from operationsTotal revenue from operations647,035.45100654,357.46100639,180.38100
Revenue from sales and services595,472.0592.03602,093.192.01586,440.2791.75
Rental revenue51,563.47.9752,264.367.9952,740.118.25
OtherOther26,581.084.1121,670.13.3110,237.31.6

Export Income

CategoryDescriptionThis YearThis Year %Last YearLast Year %2 Years Ago2 Years Ago %
Total revenueTotal revenue from operations647,035.45100654,357.46100639,180.38100
DomesticDomestic647,035.45100654,357.46100639,180.38100
InternationalInternational000000

Other Income

Operating Other IncomeNon-Operating Other IncomeShare of Profit
1710 · As of year: 26581.08 · Description: Total other income · As of yesteryear: 21670.1 · As of year before yesteryear: 10237.3 · 1711 · As of year: 0.0 · Description: Other income from operations · As of yesteryear: 0.0 · As of year before yesteryear: 0.01712 · As of year: 26581.08 · Description: Other income not from operations · As of yesteryear: 21670.1 · As of year before yesteryear: 10237.31713 · As of year: 0.0 · Description: Share of profit · As of yesteryear: 0.0 · As of year before yesteryear: 0.0

Product / Service Characteristics

Introduction

The Company has registered as a medical equipment importer in Thailand with the Food and Drug Administration under the Ministry of Public Health to comply with laws and international standards. They have been appointed as an importer and distributor of medical tools and equipment for collection, analysis, diagnosis, and medical treatment from a manufacturer of medical instruments and equipment that have been recognized for their product quality by the global medical community. The Company has been appointed as an importer and distributor of products from 34 leading manufacturers in 12 countries (including the United States, the United Kingdom, Germany, Sweden, South Korea, Singapore, China, India, Hong Kong, Japan, Hungary, and Australia) which are appointed as both Exclusive distributor and non-exclusive distributor.

In addition to the medical equipment sales mentioned above, the Company and its subsidiaries also sell consumer products, including mosquito and other blood-sucking insect trapping devices, as well as HPV & STIs Self-Collect test kits for cervical cancer screening and sexually transmitted infections, which are designed for use by all genders.

Additionally, the Company is involved in the medical laboratory service business, providing medical examination and diagnosis services with the use of high-end automated analytical tools, in accordance with medical and scientific standards.

The Company and its subsidiaries divide products and services into 3 main groups as follows:

  1. Medical Product

  2. Consumer Product

  3. Medical Services

The company and its subsidiaries have the following products and service details:

  1. Medical Product

The company operates as an importer and distributor of diagnostic kits, medical and scientific instruments, and equipment used for collection, analysis, diagnosis, and treatment. These products are imported from foreign countries and sold to domestic customers. The products and services are sold in three forms:

  1. Sale of reagents, equipment kits, and diagnostic kits.

  2. Sale of various instruments and equipment, such as blood refrigerators, plasma freezers, and blood platelet agitators (which do not require equipment kits or diagnostic kits), as well as automatic blood component separators. Additionally, the company offers stem cell separation equipment and products related to cytology and molecular microbiology.

  3. Services for detecting fetal abnormalities, as the company imports and distributes products from foreign companies with expertise in selling equipment kits and diagnostic kits. The company also invests in purchasing diagnostic machines and installs them for customers, ensuring the machines are ready for use. A contract is made with customers to purchase a minimum number of diagnostic kits within a specified time to facilitate the operation of hospitals and align procurement policies, which often specify the specifications of diagnostic kits as part of the Terms of Reference (TOR).

Thus, medical products can be categorized into three main product groups as follows:

Business Type

3115

Business Groups

Business GroupDescription
WINMED Health Center

Research & Development

Has R&D Policy (Y/N)

Yes

R&D Cost — Description

The Company places strong emphasis on supporting research and development (R&D) in medical technology, particularly the application of Artificial Intelligence (AI) in disease screening. This aims to enhance efficiency, accuracy, and accessibility to healthcare services. The Company is currently advancing two key projects as follows:

1. Breast Cancer Screening with Thermogram AI
The Company has developed and implemented Thermogram AI technology for breast cancer screening. This innovation is non-invasive, painless, and does not involve radiation. It utilizes AI to analyze thermal images of the breast to detect abnormalities, thereby supporting broader access to screening services, especially in areas with limited healthcare resources.
2. AI Colposcope Project
The Company has collaborated with the Thai Gynecologic Cancer Society and research teams from 16 medical institutions to conduct clinical research using an AI-powered colposcope. This technology captures and analyzes cervical images to detect abnormalities. The research is conducted in compliance with ethical and legal standards, with the objective of collecting and analyzing scientific data, advancing medical knowledge, and supporting the development of AI in healthcare.

The AI system assists in image analysis and supports physicians’ decision-making, improving screening accuracy and increasing the likelihood of early detection of cervical cancer.

R&D Cost — Label

Research and development (R&D) expenses over the past 3 years (Million Baht)

R&D Cost — This Year

5.73

R&D Cost — Last Year

1.03

R&D Cost — 2 Years Ago

0.0

Assets Used in the Business

Permanent Assets — Description

As of December 31, 2025, the Company has fixed assets used in business operations as follows:

List

Property Characteristics

Ownership

Netbook value at

31 Dec. 2025

(million baht)

Obligation

property utilization

Land

-

WINMED

120,209,437.09

-

used in operations

Building-Office

-

WINMED

13,385,896.10

-

used in operations

Building-Warehouse

-

WINMED

33,355,333.40

-

used in operations

Land improvements

-

WINMED

1,900,158.62

-

used in operations

Building improvements

-

WINMED and AND

29,139,537.00

-

used in operations

Computers and equipment

-

WINMED and AND

5,328,057.94

-

used in operations

Furnishings

Office furnishings used in the company's building

WINMED and AND

4,510,596.77

-

used in operations

office equipment

Office appliances used in the company's office building

WINMED

4,383,665.78

-

used in operations

Appliances

-

WINMED and AND

5,414,261.71

-

used in operations

medical equipment/1

Equipment for various analyses

WINMED

134,137,780.97

-

Accessories for use in conjunction with the products that the company sells, including equipment kits and reagent kits.

Vehicles

Vehicles used in operations

WINMED and AND

24,976,518.84

-

used in operations

Solar energy system

-

WINMED

477,106.15

-

used in operations

Assets under installation/2

Assets under construction and installation

WINMED

10,422,256.36

-

used in operations

Total equipment

387,640,606.73

Remarks:

/1 Medical equipment refers to the machinery that the company installs in various hospitals, which will be used in conjunction with the equipment and solution set that the company sells. The company has rental income from the installation of the medical equipment in question to various hospitals.

/2 Assets under installation refer to the value of computer software that is in the trial usage phase.

Intangible Assets — Description

As of 31 December 2025, the Company and its subsidiaries had net intangible assets amounting to THB 39.70 million, consisting of computer software, research and development, website, intangible assets under installation, and research under development.

Has Subsidiaries Investment Policy (Y/N)

No

Marketing Policy & Competition

Reporting Mode

3117

Marketing Policy (Overall)

Marketing Strategy

Product Strategy

The Company focuses on developing and selecting high-quality and innovative products to meet customer needs. The key approaches are as follows:

  1. Selection of High-Quality Products:
    The Company carefully selects test kits, medical and scientific instruments, and equipment from leading global manufacturers for storage, analysis, diagnosis, and treatment purposes. Emphasis is placed on products that are of high quality and widely accepted within the medical community.
    2. Introduction of Medical Innovations and Technologies:
    The Company emphasizes the adoption of advanced technologies, such as blood safety technology (Pathogen Inactivation: PI / Intercept), artificial intelligence (AI) for diagnostics (Thermogram AI and CerviCARE AI), as well as Cell & Molecular technologies, to enhance the efficiency of treatment and diagnosis.
    3. Product Development to Meet Market Needs:
    The Company develops products and services to align with the needs of all customer segments, including hospitals, government agencies, and general consumers (B2C). This ranges from self-collection test kits (Self-Collect Test) and household health products to mosquito and blood-sucking insect traps, aiming to support healthcare and improve the quality of life in everyday living.
    4. Standards and Safety Certifications:
    The Company’s products are certified by international manufacturers and registered with relevant regulatory authorities in Thailand. Key standards include:

  • Good Manufacturing Practice (GMP)

  • Quality Management Systems such as ISO 9001 and ISO 13485

  • European medical device standards (CE Mark)

  • U.S. Food and Drug Administration standards (U.S. FDA)

  • Registration with the Thai Food and Drug Administration (Thai FDA)
    5. Enhancement of Operational Standards:
    The Company has obtained additional certifications to strengthen confidence in its end-to-end operations, including:

  • Good Distribution Practice (GDP)

  • Occupational Health and Safety Management System (ISO 45001:2018)

  • Road Traffic Safety Management System (ISO 39001:2012)

  1. Product Warranty Policy:
    The Company provides product warranties covering defects in medical instruments and equipment for a period of 1–2 years after purchase or installation. Examples include blood storage refrigerators, plasma freezers, platelet storage units, and platelet agitators.

  2. After-Sales Service by Expert Team:
    The Company places strong emphasis on after-sales service by employing a team of highly trained technical specialists certified by manufacturers and possessing expertise in medical devices. The team is responsible for installation, inspection, maintenance, and troubleshooting. A service request system is also in place to facilitate fast and efficient customer support, minimizing equipment downtime and ensuring continuity in medical services, while enhancing long-term customer trust and satisfaction.

Pricing Strategy (Price)

The Company and its subsidiaries adopt a cost-plus pricing policy, which involves setting selling prices based on product costs plus an appropriate profit margin. Product costs include purchase costs from manufacturers, transportation expenses, import duties, import-related expenses, and other relevant costs.

In determining selling prices, the Company also considers economic conditions, competitive landscape, and customer order value and volume. Additionally, the Company consistently enters into forward foreign exchange contracts with financial institutions to mitigate risks from exchange rate fluctuations associated with importing products from overseas.

The Company does not adopt a price competition or price-cutting strategy to compete with other market players. Instead, it focuses on offering high-quality products, differentiated technologies, internationally recognized standards, and delivering added value to its partners and patients.

Distribution Channel Strategy (Place)

The Company utilizes two primary channels for product presentation and/or distribution, as follows:

1. Offline Channel

This channel mainly involves medical products, with distribution approaches as follows:

1.1 Direct Sales by Sales Representatives:
Sales personnel directly present products to clinics, hospitals, the National Blood Centre of the Thai Red Cross Society, and laboratories. They are also responsible for coordinating sales activities and negotiating according to customer requirements, such as providing product trials or organizing academic seminars related to the Company’s products.

1.2 Direct Purchases from the Company:
Customers may directly purchase products from the Company. Due to the high quality of its products and strong customer satisfaction, the Company has gained recognition through word-of-mouth within the medical community and among healthcare professionals.

1.3 Government Procurement and Bidding:
The Company participates in procurement processes of various institutions, including government hospitals, the National Blood Centre of the Thai Red Cross Society, and medical schools. When the Company meets the qualifications specified in procurement announcements, it prepares and submits bidding documents accordingly. The Company also assigns personnel to continuously monitor procurement announcements through various channels.

1.4 Retail Distribution Channels:
Products are also distributed through department stores, pharmacies, and convenience stores, such as mosquito traps and self-collection screening kits for cervical cancer and sexually transmitted infections (HPV & STIs Self-Collect Test).

1.5 Public Sector Collaboration:
The Company has expanded its service channels through collaboration with the public sector by entering into Memorandums of Understanding (MOUs) with Provincial Administrative Organizations in multiple regions to implement cervical cancer screening programs for women. These initiatives aim to enhance access to primary healthcare services for target populations in an inclusive and equitable manner, supported by funding from the National Health Security Office (NHSO), a key mechanism driving proactive screening at the community level.

1.6 Collaboration with Leading Government Hospitals:
The Company collaborates with leading public hospitals across different regions to promote access to blood and platelet donation services, helping to alleviate shortages in the overall blood supply. The Company has expanded its investment in blood donation programs by adding two mobile automated blood collection units, capable of collecting both red blood cells and platelets. Currently, the Company operates such mobile platelet donation units in collaboration with 20 hospitals nationwide.

2. Online Channels

The Company and its subsidiaries place strong emphasis on customer convenience and accessibility to product information. Therefore, they have continuously developed communication and distribution channels through online platforms to enhance convenience and improve access to the Company’s products and services. The Company’s and its subsidiaries’ online channels include:

  • Company Website: https://www.winmed.com and subsidiary website https://anewday.co.th

  • E-commerce Platforms: Shopee, Lazada, and LINE MyShop

  • Social Media Channels: Facebook, Instagram, TikTok, X, and LINE

  • “Pedsupab” Page: A platform providing knowledge on sexual health and disease prevention for the public

  • “342” Page: Used as a channel to communicate product information, activities, and customer engagement

  • Online Booking System: For scheduling appointments at the Company’s clinic to enhance convenience, reduce waiting time, and improve customer experience

Most products sold through online channels are consumer goods suitable for household use, such as mosquito and blood-sucking insect traps, and self-collection test kits for cervical cancer and sexually transmitted infections (HPV & STIs Self-Collect Test).

Marketing and Promotion Strategy

The Company conducts marketing and promotional activities through academic seminars at the national level, hospital-based events, and participation in exhibition booths at annual academic conferences organized by various associations, such as the Medical Technology Association of Thailand, the Royal Thai College of Obstetricians and Gynaecologists, the Thai Gynecologic Cancer Society, the National Blood Centre of the Thai Red Cross Society, hospitals, and leading medical faculties.

With over 30 years of experience in distributing diagnostic and therapeutic medical products and equipment, the Company has gained strong recognition and trust among medical professionals.

Since late 2023, the Company has entered into Memoranda of Understanding (MOUs) with more than 20 provinces to promote access to cervical cancer screening for women across Thailand. This initiative has been well received and expanded into proactive healthcare programs under the “Mobile Health Check Caravan” project in collaboration with Provincial Administrative Organizations.

Examples of Marketing and Promotional Activities in 2025

  • Sponsorship of medical academic conferences, product exhibitions, and MOU signings for cervical cancer screening campaigns

  • Health caravan and Mobile Colposcopy project providing comprehensive and convenient cervical cancer screening services

  • CSR activities in collaboration with Kamphaeng Phet Provincial Administrative Organization and Health Region 3

  • Blood and platelet donation campaigns in collaboration with Ramathibodi Hospital

  • Free breast cancer screening services using Thermogram AI technology

Online Marketing Activities

  • AVA Diagnostics (Instagram, Facebook, Shopee, Lazada): Promoting AVA Self-Collect Test by Winmed

  • Blackhole Mosquito Trap (Facebook, TikTok, LINE, Shopee, Lazada, YouTube)

  • Pedsupab (Pedsupab.Official) (Instagram, Facebook, TikTok, Threads, X, YouTube): Health education content aligned with company products

  • “342” Page (Instagram): Product communication and engagement

Additionally, the Company has launched LinkedIn and Facebook pages under the name “Winnergy Medical” to share corporate updates and activities.

Competitive Strategy / Business Growth / Competitive Advantages

  • Strong portfolio of comprehensive medical products covering screening and diagnosis, with nationwide accessibility through partners and service networks

  • Market leadership in medical product distribution, especially in WINMED Cancer Care, WINMED Blood Solutions, and WINMED Life Sciences

  • Continuous trust from international manufacturers as a long-term distributor in Thailand

  • Strong quality control and customer satisfaction evaluation processes, particularly among government and private hospital clients

  • Continuous sourcing of innovative and high-performance medical products by experienced professionals

  • Expansion into Medical Consumer products, such as HPV & STIs self-collection test kits for all genders

  • Broadened customer base to include corporate and individual customers, along with expanded online distribution channels

Strategic Initiatives

The Company has initiated projects with Provincial Administrative Organizations to promote equitable access to basic healthcare services. These projects are funded under the National Health Security Office (NHSO).

The Company also promotes self-screening for cervical cancer and has expanded investments in mobile automated blood donation units capable of collecting both red blood cells and platelets.

As of 2025, the Company operates mobile platelet donation units in collaboration with 20 hospitals, categorized as follows:

  • Central and Eastern Regions (7 hospitals): Rajavithi Hospital, Ramathibodi Hospital, Thammasat Hospital, Vajira Hospital, Chonburi Hospital, Phramongkutklao Phetchaburi Hospital, and Srinakharinwirot University

  • Northeastern Region (8 hospitals): Khon Kaen Hospital, Roi Et Hospital, Chaiyaphum Hospital, Buriram Hospital, Wang Saphung Hospital, Kalasin Hospital, Nakhon Ratchasima Hospital, and Maharaj Nakhon Ratchasima Hospital

  • Southern Region (5 hospitals): Vachira Phuket Hospital, Yala Hospital, Trang Hospital, Surat Thani Hospital, and Songkhla Hospital





Industry & Competition (Overall)

Over the past year, Thailand’s medical device and healthcare technology industry has experienced continuously increasing competition from both domestic and international players, particularly in the areas of diagnostics, screening, and advanced medical technologies. Meanwhile, healthcare demand continues to grow, driven by an aging society, the rising prevalence of non-communicable diseases (NCDs), and persistently high cancer mortality rates in Thailand.

These factors have led to a steady increase in demand for early-stage screening and diagnostic services, supporting the long-term growth potential of the medical device market.

Industry Outlook and Competitive Landscape

Competition within the industry is expected to intensify further, with emerging technologies such as Artificial Intelligence (AI) and Precision Medicine playing increasingly significant roles. Companies that are able to integrate technology with service accessibility, and establish strong collaborations with government agencies, are likely to gain a long-term competitive advantage.

Number of Competitors

The Company faces competition from both domestic and international players. The number of competitors varies depending on the product category within each business segment. Overall, the market consists of numerous participants, particularly importers and distributors of medical devices.

Company Size Compared to Competitors

The Company is considered a mid-sized operator within the industry. Its strengths lie in specialized expertise and an integrated business model encompassing products, services, and public health initiatives. These capabilities enable the Company to compete effectively with larger players in certain product segments.

Competitive Environment and Capability

The Company benefits from several competitive advantages, including strong collaborative networks with hospitals, government agencies, and medical partners, as well as its ability to offer specialized technologies such as blood safety technology (Pathogen Inactivation: PI) and AI-based diagnostic solutions.

In addition, the Company’s Mobile Health Caravan project, implemented in collaboration with Provincial Administrative Organizations, represents a key strength. This initiative enables the Company to reach communities at the local level and support proactive health screening programs on a broad scale. The Company is regarded as one of the key operators in this area, creating differentiation and enhancing its competitive advantage.

Competitors (in Case of Limited or Niche Competition)

In the area of proactive health screening services through Mobile Health Caravan projects in collaboration with Provincial Administrative Organizations, the Company operates a differentiated model supported by systematic, area-based collaboration. Currently, there are no other operators capable of delivering services in the same integrated manner.

This is due to the Company’s readiness in terms of medical technology, its strong network with government agencies and healthcare institutions, and its extensive experience in implementing community-level screening programs. As a result, the Company is able to integrate the entire service process efficiently from screening and coordination with local authorities to connecting patients with appropriate treatment pathways.


Quantitative Competitive Landscape of the Company within the Industry

Details are as follows:

Analysis Dimension

Quantitative Data / Estimates

Impact Analysis on WINMED

Thailand Medical Devices Market Value

Approximately THB 270,000 – 320,000 million per year (growing from 2024 in line with increased healthcare investment)

WINMED operates as a small-to-medium-sized distributor in the diagnostics and specialized services segments

Molecular Diagnostics Market Value (Thailand)

Approximately THB 1,000 million (2025, Grand View Research)

WINMED has product offerings in this segment, with an estimated market share of 7–18%

HPV Self-Collect / Cervical Screening Market Value (Public Sector)

Approximately THB 700 million per year (driven by government screening programs and NHSO budget)

WINMED is one of the key distributors, with an estimated market share of 10–30%

WINMED Total Revenue (2025)

Approximately THB 647 million

Reflects the Company’s role as an integrated medical solutions provider, focusing on B2G and B2B markets

Number of Competitors in Diagnostics / HPV / Cytology Market

≥ 10–15 players (including manufacturers and distributors)

WINMED competes with companies offering global-standard technologies but holds advantages in hospital networks, government projects, and strong relationship management

Sources: Krungthai COMPASS, KResearch, BOI, Grand View Research, Annual Report of the National Health Security Office (NHSO)

Procurement of Products & Services

Reporting Mode

3117

Procurement (Overall)

The Company operates a business involving the importation and distribution of medical diagnostic kits, medical devices, and scientific equipment used for storage, analysis, diagnosis, and/or prevention, monitoring, treatment, or alleviation of diseases. The Company carefully selects products from reputable international manufacturers that meet high-quality standards, are reliable, and are certified in accordance with international standards, such as the European Conformity (CE Mark) and approvals from the United States Food and Drug Administration (U.S. FDA), among others.

At present, the Company has been appointed as an importer and distributor of medical diagnostic kits and medical devices by leading global manufacturers located in several countries, including Germany, the United States, Spain, and the Republic of Korea. The Company negotiates and enters into agreements with such manufacturers to obtain distribution rights under the manufacturers’ brands, subject to mutually agreed terms and conditions. The Company selects only manufacturers that are internationally recognized within the medical industry and are duly certified by regulatory authorities in their respective countries.

As the importation of medical devices in Thailand is regulated under the Medical Device Act B.E. 2551 (2008), as amended (B.E. 2562 (2019)), as well as other related standards, the Company is required to register as a licensed medical device importer with the Medical Device Control Division under the supervision of the Food and Drug Administration, Ministry of Public Health. In addition, medical devices imported for distribution in Thailand must undergo notification, detailed listing, or licensing procedures, depending on their classification and risk level.

These regulatory requirements ensure that all medical devices distributed domestically have been evaluated and certified by the relevant Thai regulatory authorities. To comply with such legal requirements, the Company has duly registered as a medical device importer with the relevant government agencies and has prepared all necessary documentation for product registration in accordance with the criteria set by the Food and Drug Administration. The operational process is as follows:

For the procurement of diagnostic test kits, medical diagnostic products, medical devices and equipment, as well as mosquito trapping products, all of which are imported from overseas. The Company utilizes import financing instruments, including Letters of Credit (L/C) and Trust Receipts (T/R).

The sales team and relevant departments plan product procurement based on projected sales for each product category, taking into account customer demand, existing inventory levels, and delivery lead times. In general, the Company maintains inventory sufficient for approximately 2–3 months of sales, depending on the product type.

However, for certain medical devices for which demand cannot be accurately forecast in advance such as platelet storage refrigerators and plasma storage freezers procurement will be made only upon receiving confirmed purchase orders from customers.

In placing orders from overseas suppliers and making payments in foreign currencies, the Company has established forward exchange contracts with financial institutions to mitigate risks arising from foreign exchange rate fluctuations.

Procurement Process Flow

Significant Contracts Related to Business Operations

  • Appointment Agreement as Importer and Distributor

    Counterparty

    Contract Country

    Partner Country

    Year of Initial Appointment

    Contract Term

    Nature of Relationship (Importer & Distributor)

    1. Haemonetics (Hong Kong) Ltd.

    Hong Kong

    USA

    1996

    1 Apr 2024 – 31 Mar 2026

    Exclusive Distributor

    2. Miltenyi Biotec Asia Pacific Pte Ltd.

    Singapore

    Germany

    2000

    26 Mar 2025 – 25 Mar 2026

    Non-Exclusive Distributor

    3. Hologic Asia Pacific Limited

    Hong Kong

    USA

    2003

    1 Oct 2024 – 30 Sep 2026

    Non-Exclusive Distributor

    4. Helmer Inc.

    USA

    USA

    2006

    9 Jul 2018 – 31 Dec 2026

    Letter of Authorization

    5. OriGen Biomedical

    USA

    USA

    2006

    15 Nov 2024 – 14 May 2027

    Non-Exclusive Distributor

    6. Centron Corporation

    Republic of Korea

    Republic of Korea

    2012

    1 Jan 2025 – 31 Dec 2027

    Exclusive Distributor

    7. WAK-Chemie Medical

    Germany

    Germany

    2013

    Until terminated by either party

    Letter of Authorization

    8. Cerus Corporation

    USA

    USA

    2014

    15 Nov 2022 – 31 Dec 2028

    Exclusive Distributor

    9. NanoEnTek Inc.

    Republic of Korea

    Republic of Korea

    2018

    7 Jul 2023 – 30 Jun 2027

    Non-Exclusive Distributor

    10. Dacor Manufacturing, LLC

    USA

    USA

    2018

    1 Jan 2025 – 31 Dec 2026

    Non-Exclusive Distributor

    11. Conroy Medical AB

    Sweden

    Sweden

    2018

    2 Sep 2020 – 11 May 2027

    Letter of Authorization

    12. Zebra Technologies International, LLC (Temptime Corporation)

    USA

    USA

    2021

    26 Aug 2025 – Indefinite

    Letter of Authorization

    13. SEILER INSTRUMENT & MFG CO INC.

    USA

    USA

    2021

    1 Jan 2021 – 9 Jul 2026

    Letter of Authorization

    14. Biologix Plastics (Changzhou) Co., Ltd.

    China

    China

    2022

    1 May 2022 – 31 Dec 2028

    Non-Exclusive Distributor

    15. Thermo Fisher Scientific (Life Technologies Holding Pte Ltd)

    Singapore

    Singapore

    2022

    17 Oct 2022 – 31 Dec 2026

    Non-Exclusive Distributor

    16. NIRAMAI Health Analytix Private Limited

    India

    India

    2023

    30 Jun 2023 – 29 Jun 2026

    Exclusive Distributor

    17. Life Science Group Ltd.

    UK

    UK

    2023

    15 Dec 2023 – 15 Dec 2026

    Non-Exclusive Distributor

    18. Weigao Medical International Co., Ltd. (WEGO)

    China

    China

    2023

    26 Mar 2024 – 25 Mar 2027

    Non-Exclusive Distributor

    19. GenScript Biotech (Singapore) PTE Ltd.

    Singapore

    Singapore

    2023

    4 Jan 2024 – 31 Dec 2026

    Non-Exclusive Distributor

    20. NTL Healthcare Co., Ltd.

    Republic of Korea

    Republic of Korea

    2023

    14 May 2024 – 1 Aug 2028

    Non-Exclusive Distributor

    21. Singuway Biotech Inc.

    China

    China

    2024

    18 Jul 2024 – 30 Sep 2027

    Non-Exclusive Distributor

    22. SHANGHAI ZJ BIO-TECH Co., Ltd. (Liferiver)

    China

    China

    2024

    21 Jun 2024 – Indefinite

    Non-Exclusive Distributor

    23. Wuhan BMS Medicaltech Co., Ltd

    China

    China

    2025

    19 Mar 2025 – 18 Mar 2028

    Letter of Authorization

    24. Poly Medicure Limited

    India

    India

    2025

    11 Dec 2025 – 10 Dec 2028

    Non-Exclusive Distributor

    25. ZENOGEN PHARMA Co., Ltd.

    Japan

    Japan

    2025

    1 Apr 2025 – 31 Mar 2026

    Non-Exclusive Distributor

    26. Tianjin Dexiang Biotechnology Co., Ltd.

    China

    China

    2025

    31 Dec 2025 – 31 Dec 2030

    Exclusive Distributor

    27. Digiterm Ltd.

    Hungary

    Hungary

    2025

    8 May 2025 – 7 May 2028

    Exclusive Distributor

    28. GENEFIRST Ltd

    UK

    UK

    2025

    13 Nov 2025 – 12 Nov 2026

    Exclusive Distributor

    29. Typenex Medical LLC

    USA

    USA

    2025

    13 Nov 2025 – 12 Nov 2027

    Non-Exclusive Distributor

    30. Genepoint Technologies (Shanghai) Co., Ltd.

    China

    China

    2025

    3 Jan 2025 – 3 Jan 2027

    Non-Exclusive Distributor

    31. Qingdao Haier Biomedical Co., Ltd

    China

    China

    2025

    27 May 2025 – 26 May 2026

    Non-Exclusive Distributor

    32. Paragon Care Group Australia Pty Ltd

    Australia

    Australia

    2025

    1 Jul 2025 – 30 Jun 2028

    Non-Exclusive Distributor

    33. Shanghai GeneoDX Biotech Co., Ltd.

    China

    China

    2025

    23 Dec 2025 – 22 Dec 2030

    Exclusive Distributor

    34. Genetimes ExCell Technology, Inc.

    China

    China

    2025

    22 Dec 2025 – 31 Dec 2027

    Non-Exclusive Distributor

Projects Under Construction

Has Projects Under Construction (Y/N)

No

Debentures & Bills of Exchange

Has Debentures (Y/N)

No

Convertible Securities

Has Convertible Securities (Y/N)

No

Contents